{"entity":{"id":"nct07585279","kind":"trial","name":"A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer","aka":[],"tldr":"A phase 2/3 trial of irinotecan (and liposomal irinotecan), fluorouracil (5-FU), leucovorin (folinic acid), bevacizumab (glioblastoma use) and other drugs in colorectal cancer, run by Hebei Medical University Fourth Hospital, not yet recruiting.","summary":"A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer is a phase 2/3, randomised interventional study registered as NCT07585279 by Hebei Medical University Fourth Hospital, with a registry enrolment figure of 408 participants, started 2026-05-20 and due to reach its primary completion in 2031-02-28. Interventions recorded: Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart; Irinotecan liposome + 5-FU/LV + Bevacizumab; Irinotecan + 5-FU/LV + Bevacizumab. Conditions listed: Metastatic Colorectal Cancer (CRC); Liposomal Irinotecan; Second-Line. Primary outcome: ORR. Colorectal eligibility wording from the registry: \"Histologically or cytologically confirmed metastatic colon or rectal adenocarcinoma;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07585279","url":"https://clinicaltrials.gov/study/NCT07585279"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","topoisomerase-inhibitors"],"targets":[],"drugs":["irinotecan","fluorouracil","leucovorin","bevacizumab-glioma","folfiri"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07585279","phase":"2/3","setting":"Liposomal Irinotecan-based Regimen Versus Irinotecan-based Regimen in Second-Line Treatment for Metastatic Colorectal Cancer (IRIS-02): A Randomized, Controlled Phase II/III Study","sponsor":"Hebei Medical University Fourth Hospital","enrolled":408,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07585279/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"irinotecan","kind":"drug","name":"Irinotecan (and liposomal irinotecan)","route":"/drugs/irinotecan/"},{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}